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placebo group received subsequent life-extending 
therapy at the time of data cutoff. At that time, of 
the 251 patients in the placebo group who had 
not received subsequent life-extending therapy, 
24% continued to receive placebo, 19% received 
other therapies, and 43% died before receiving 
any subsequent therapy. We would suggest that 
the timing of chemotherapy in such patients has 
not been shown to affect survival and that the 
post-progression treatment experience of our study 
patients reflects the standard of care.
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To the Editor: In their review article, Brouwer 
et al. (July 31 issue)1 suggest the use of vancomy-
cin for the treatment of brain abscesses caused 
by methicillin-resistant Staphylococcus aureus (MRSA). 
However, regarding this choice, there are some 
concerns that should be considered.
First, vancomycin has poor cerebrospinal fluid 
(CSF) penetration when administered at a stan-
dard dose; thus, larger doses should be adminis-
tered to achieve adequate CSF levels. However, 
high vancomycin serum concentrations are inde-
pendently associated with nephrotoxicity.2 Sec-
ond, dexamethasone, used for the management of 
brain edema, can substantially reduce the penetra-
tion of vancomycin into CSF.3 Third, infections 
caused by MRSA strains with high minimum in-
hibitory concentrations of vancomycin have been 
associated with increased treatment failure and 
mortality when vancomycin is used empirically.4
Here, we pose the question of whether it is time 
to review the current approach to antibiotic ther-
apy. We believe that, as first-line empirical treat-
ment for brain abscesses caused by MRSA, newer 
antibiotic agents, such as linezolid, that achieve 
higher CSF levels than those observed with van-
comycin should be used.5 Although interindi-
vidual variability has been reported, an increasing 
number of reports have shown the efficacy of 
linezolid for the treatment of brain abscesses.
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To the Editor: In their review article, Brouwer 
and colleagues recommend the standard four-
drug regimen (isoniazid, rifampin, pyrazinamide, 
and ethambutol) for the treatment of brain ab-
scesses due to Mycobacterium tuberculosis. This rec-
ommendation is in accordance with current 
guidelines1; nevertheless, it must be noted that 
although this regimen has been studied exten-
sively in patients with respiratory tuberculosis, 
there is a scarcity of data regarding its use for the 
treatment of brain abscesses.
Pharmacokinetic studies2 have shown that the 
CSF penetration of ethambutol is poor, with neg-
ligible concentrations in patients without menin-
gitis. In contrast, f luoroquinolones, which have 
good activity against M. tuberculosis, reach CSF 
levels well above the minimum inhibitory con-
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA DEGLI STUDI DI MILANO on April 8, 2019. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
correspondence
n engl j med 371;18 nejm.org october 30, 2014 1757
centrations,3,4 although an unequivocal benefit in 
tuberculous meningitis has not been proved.5
Available pharmacokinetic data should induce 
some caution in recommending the use of etham-
butol for the treatment of tuberculosis of the 
central nervous system and should discourage 
the use of low doses of ethambutol (15 mg per 
kilogram of body weight). However, the use of 
fluoroquinolones in combination with isoniazid, 
rifampin, and pyrazinamide may deserve consid-
eration in the treatment of this severe condition.
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To the Editor: The article by Brouwer et al. 
mentions several causes of brain abscesses but 
does not include paracoccidioidomycosis. This fun-
gal disease is the most common systemic endemic 
mycosis in Central America and South America 
(but with increasing incidence in Europe and 
North America) and is the eighth highest cause 
of death (1.45 deaths per 1 million inhabitants per 
year) from chronic infectious disease in Brazil.1,2
The prevalence of central nervous system in-
volvement in paracoccidioidomycosis (neuropara-
coccidioidomycosis) is approximately 10% and 
can reach 36% with more aggressive use of 
neuroimaging.3 However, it is frequently under-
recognized and underreported. Neuroparacoccidi-
oidomycosis presents as brain lesions (abscess, 
granuloma, nodule, or cyst) in 90% of cases and 
as meningitis in 10%, is associated with a strik-
ing mortality of 44%, and causes substantial 
sequelae in approximately half the survivors.3,4
Consequently, this fungal disease should be con-
sidered in patients with brain abscess, especially 
in those with concomitant oral lesions, micro-
stomia, skin ulcerations, diffuse pulmonary in-
filtrates, or adrenal abnormalities (Fig. 1).1,3,4
This high clinical suspicion may allow early di-
agnosis and treatment, possibly reducing mor-
tality and sequelae.
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Figure 1. Possible Concomitant Findings in Patients 
with Neuroparacoccidioidomycosis.
Panel A shows microstomia, Panel B skin ulcerations, 
and Panel C pulmonary infiltrates (reversed halo sign).
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The Authors Reply: We agree with the concern 
regarding vancomycin penetration into the CSF, 
although a study has shown that the administra-
tion of high doses of intravenous vancomycin 
(60 mg per kilogram per day as a continuous in-
fusion, after a loading dose of 15 mg per kilo-
gram), even with the concomitant administra-
tion of dexamethasone, in patients with bacterial 
meningitis led to adequate CSF concentrations 
(7.9 μg per milliliter),1 suggesting that the de-
creased penetration can be overcome with the 
administration of appropriate parenteral doses.
With regard to the penetration of vancomycin 
into brain abscesses, there are limited data. In one 
case report in a patient with an S. aureus–associ-
ated brain abscess, simultaneous measurements 
of vancomycin concentrations in serum and brain-
abscess fluid were obtained 1 hour after the in-
travenous administration of a 500-mg dose. 
Vancomycin levels obtained from the brain-ab-
scess fluid before and during operative removal of 
the abscess were 15 μg per milliliter and 18 μg 
per milliliter, respectively; the serum vancomy-
cin level was 21 μg per milliliter.2 Pending fur-
ther data, we continue to recommend treatment 
of brain abscesses caused by MRSA with vanco-
mycin. However, careful monitoring of these pa-
tients is critical, and we agree that salvage thera-
py with relatively new agents (such as linezolid 
or daptomycin) should be used in patients with 
brain abscesses caused by MRSA strains who do 
not have a response or who have an elevated 
minimum inhibitory concentration of vancomycin.
The advised standard four-drug treatment 
regimen (isoniazid, rifampin, pyrazinamide, and 
ethambutol) for tuberculous brain abscesses is 
recommended in the current World Health Or-
ganization guidelines for tuberculosis of the 
central nervous system. Despite the excellent 
penetration of moxifloxacin into the CSF, a sur-
vival benefit with that drug in tuberculous men-
ingitis has not been shown.3 Levofloxacin is 
currently being evaluated in a randomized, con-
trolled trial involving patients with tuberculous 
meningitis.4 If this study shows benefits with 
levofloxacin, it would seem prudent to incorpo-
rate this agent into the treatment regimen for 
tuberculous brain abscesses.
In a recent meta-analysis that included 9699 
patients with brain abscess, fungi comprised only 
a minority of cases (1.4%),5 and paracoccidioido-
mycosis was rarely reported as an etiologic 
agent. However, we agree that neuroparacoccidi-
oidomycosis should be strongly considered, in 
the appropriate clinical setting, as a cause of 
brain abscess in inhabitants of, and travelers 
from, regions in which this disease is endemic.
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